Essentially, SLE patients (n = 6) demonstrated lower levels of serum IL-17 and reduced proportion of CD3+CD8-IL-17+ Th17 cells after receiving 4 weeks of treatment with hydroxychloroquine and prednisone (27). The gene discussed is IL17A; the disease is systemic lupus erythematosus.